3 blue chip ASX 200 shares I’d happily buy and hold through the next decade

One of the biggest mistakes investors can make is assuming that blue chip shares are boring.

They may not deliver the explosive short-term gains sometimes seen with small caps, but the right blue-chip ASX 200 share can quietly build enormous wealth over time.

This is because they tend to dominate their industries, generate strong cash flows, and reinvest heavily to stay ahead.

On the ASX 200, there are a number of shares that have demonstrated this ability repeatedly. Here are three blue chip shares that stand out as long-term compounders.

ResMed Inc. (ASX: RMD)

The first blue chip ASX 200 share that could be a buy is ResMed.

At first glance, ResMed looks like a medical device manufacturer selling sleep apnoea machines. But there’s more to it than just that. Each device connects patients, doctors, and healthcare providers through a growing digital health platform.

This network effect is quietly strengthening the business. Every new device adds another patient to ResMed’s ecosystem, increasing the value of its software tools for clinicians and insurers.

With sleep apnoea still massively underdiagnosed globally, the runway for growth remains long. Millions of people who need treatment are yet to be identified, which gives ResMed years of potential expansion ahead.

That combination of recurring device sales, software revenue, and expanding healthcare demand is what could make ResMed such a powerful long-term blue chip.

Goodman Group (ASX: GMG)

Another blue chip ASX 200 share that deserves attention is Goodman Group.

Many investors still think of Goodman as a property developer. In reality, it has become one of the world’s most important providers of logistics and data infrastructure.

The company owns and develops warehouses, distribution hubs, and increasingly data centre facilities located near major cities. These assets sit at the heart of modern commerce.

Every time a package is delivered from an online retailer or data is processed in the cloud, infrastructure like Goodman’s is often involved somewhere in the chain.

The company also partners with global institutional investors to fund these developments, allowing it to expand while generating steady management and development income.

As ecommerce, cloud computing, and data consumption continue to grow, demand for this type of infrastructure is unlikely to slow.

Macquarie Group Ltd (ASX: MQG)

A final blue chip ASX 200 share worth considering is Macquarie Group.

Macquarie has built a reputation as one of Australia’s most globally successful financial institutions. Over the past two decades it has transformed itself from a domestic investment bank into a global infrastructure and asset management powerhouse.

The company now manages and invests in assets ranging from airports and renewable energy projects to data centres and telecommunications infrastructure.

What makes Macquarie particularly interesting is its ability to identify emerging investment themes early. Whether it was infrastructure decades ago or renewable energy more recently, the company has consistently positioned itself ahead of major capital flows.

That adaptability has allowed Macquarie to grow earnings across multiple economic cycles while continuing to reward shareholders with rising dividends.

The post 3 blue chip ASX 200 shares I’d happily buy and hold through the next decade appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Whitehaven Coal, Goodman, and Xero shares
• Leading brokers name 3 ASX shares to buy today
• If I wanted to outperform the ASX 200 over the next 10 years, I’d focus here
• Why I’d invest $5,000 in these ASX dividend shares
• This would be my $1 million ASX retirement portfolio

Motley Fool contributor James Mickleboro has positions in Goodman Group and ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goodman Group, Macquarie Group, and ResMed. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has recommended Goodman Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.